MHRA safety alerts and recalls
Every MHRA medicines recall, patient safety alert and Drug Safety Update, checked against GOV.UK every 2 hours from 07:00 to 19:00. Last checked 30 Oct, 17:00.
Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.
Recalls needing action now
Class 1–3 recalls issued in the last 14 days and National Patient Safety Alerts issued in the last 30 days.
-
RecallClass 2 · Action within 48 hoursClass 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45 Act on the official notice
-
RecallClass 2 · Action within 48 hoursClass 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44 Act on the official notice
-
RecallClass 2 · Action within 48 hoursClass 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43 Act on the official notice
What do the recall classes mean?
| Class | Action | The MHRA's definition |
|---|---|---|
| Class 1 | Immediate action | The defect presents a risk of death or disability. |
| Class 2 | Action within 48 hours | The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious. |
| Class 3 | Action within 5 days | The defect is unlikely to cause harm to the patient. |
| Class 4 | Caution in use | Usually minor defects in packaging or other printed materials. |
A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.
All alerts
85 items · page 1 of 4. Showing the community pharmacy view.
-
RecallClass 2 · Action within 48 hours
Class 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45
Accord-UK Ltd is recalling one batch of Lercanidipine Hydrochloride 10mg Tablets due to a packaging mix-up involving the incorrect strength.
GOV.UK notice Every medicines recall is shown.
-
RecallClass 2 · Action within 48 hours
Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44
Advanz Pharma Limited are recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure.
GOV.UK notice Every medicines recall is shown.
-
Roundup
MHRA Safety Roundup: October 2026
Summary of the latest safety advice for medicines and medical device users
GOV.UK notice Every MHRA monthly roundup is shown.
-
Drug Safety Update
#MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app
The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. This year's theme is ‘Side effects: don't ignore them, report them!’
GOV.UK notice Shown because the MHRA tagged it "Pharmacy".
-
RecallClass 2 · Action within 48 hours
Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43
Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel.
GOV.UK notice Every medicines recall is shown.
-
Drug Safety Update
Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction
New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications.
GOV.UK notice Shown because the MHRA tagged it "Pharmacy".
-
RecallClass 2 · Action within 48 hours
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations.
GOV.UK notice Every medicines recall is shown.
-
RecallClass 3 · Action within 5 days
Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41
Norgine Limited is recalling specific batches of product as a precautionary measure due to some units containing the incorrect amounts of active ingredients.
GOV.UK notice Every medicines recall is shown.
-
Roundup
MHRA Safety Roundup: September 2026
Summary of the latest safety advice for medicines and medical device users
GOV.UK notice Every MHRA monthly roundup is shown.
-
RecallClass 4 · Caution in use
Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39
B. Braun Melsungen AG has notified the MHRA that errors have been identified in the Patient Information Leaflet (PIL) included in some batches of Meropenem 1000 mg powder and solvent for solution for infusion.
GOV.UK notice Every medicines recall is shown.
-
RecallClass 4 · Caution in use
Class 4 Medicines Defect Notification: Martindale Pharmaceuticals Ltd, Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150ml, EL(26)A/38
Martindale Pharmaceuticals has informed the MHRA of an error with the linear barcode of some batches of Clobazam 5mg/5mL and 10mg/5mL Oral Suspension 150mL.
GOV.UK notice Every medicines recall is shown.
-
Patient Safety Alert
National Patient Safety Alert: Patient hoists and slings (all types): risk of death and serious harm from falls (NatPSA/2026/005/MHRA)
Fatal and serious harm continues to occur when patients fall from hoists or slings during transfers and repositioning. A review of recent incidents with a fatal outcome and wider surveillance data shows an average of two deaths per year since 2015.
GOV.UK notice Every National Patient Safety Alert is shown.
-
Drug Safety Update
Filters should be used during the administration of Parenteral Nutrition for patients in all care settings
Administration of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcome.
GOV.UK notice Shown because the MHRA tagged it "Pharmacy".
-
Device safety
Filters should be used during the administration of Parenteral Nutrition for patients in all care settings DSI/2026/011
Administration of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcome.
GOV.UK notice Shown because the MHRA tagged it "General practice".
-
Device safety
Cobalt-chrome modular neck hip replacements: risk of metal-wear effects and revision surgery (DSI/2026/010)
An MHRA investigation has found increased risks of wear and corrosion associated with multiple cobalt-chrome (Co-Cr) modular neck hip stem components, including a potential increased occurrence of revision surgery due to adverse local tissue reaction (ALTR).
GOV.UK notice Shown because the MHRA tagged it "General practice".
-
Roundup
MHRA Safety Roundup: August 2026
Summary of the latest safety advice for medicines and medical device users
GOV.UK notice Every MHRA monthly roundup is shown.
-
RecallClass 2 · Action within 48 hours
Class 2 Medicines Recall: Zentiva Pharma UK Limited, Fingolimod Zentiva 0.5 mg Capsules, EL(26)A/37
Zentiva UK Pharma Limited are recalling one batch of Fingolimod Zentiva 0.5 mg Capsules (BN 4L01372H) as a precautionary measure due to a potential risk of contamination with metal particles.
GOV.UK notice Every medicines recall is shown.
-
Device safety
Rectal catheters sold for personal use (gas and colic relievers): Do not use in infants, including for the treatment of colic, gas-related discomfort or constipation (DSI/2026/008)
Do not use rectal catheters sold for personal use (gas and colic relievers) in infants, including for colic, gas-related discomfort or constipation. Stop using these products immediately and dispose of any unused devices.
GOV.UK notice Shown because the MHRA tagged it "General practice".
-
Patient Safety Alert
National Patient Safety Alert: ResMed Astral 100 and 150 Ventilators: Potential for Patient Harm due to Unexpected Interruption of Ventilation Therapy (NatPSA/2026/004/MHRA)
ResMed has issued a Field Safety Notice regarding Astral 100 and 150 ventilators and associated Printed Circuit Board Assembly spare parts manufactured prior to October 2024. A fault in the device can cause unexpected interruption of ventilation therapy.
GOV.UK notice Every National Patient Safety Alert is shown.
-
Device safety
Devices supplied without valid UKCA/CE conformity markings or certification: remove from use and place in quarantine (DSI/2026/007)
The MHRA has become aware of a number of medical devices being supplied on the UK market that do not comply with the requirements of the UK Medical Device Regulations 2002 (UK MDR 2002) or with the EU Medical Devices Regulation (EU) 2017/745 (EU MDR).
GOV.UK notice Shown because the MHRA tagged it "Pharmacy".
-
Roundup
MHRA Safety Roundup: July 2026
Summary of the latest safety advice for medicines and medical device users
GOV.UK notice Every MHRA monthly roundup is shown.
-
RecallClass 4 · Caution in use
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and 40mg chewable tablets.
GOV.UK notice Every medicines recall is shown.
-
Drug Safety Update
Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.
GOV.UK notice Shown because the MHRA tagged it "Pharmacy".
-
RecallClass 4 · Caution in use
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles.
GOV.UK notice Every medicines recall is shown.
-
RecallClass 2 · Action within 48 hours
Class 2 Medicines Recall: Beckton Dickson UK Ltd, ChloraPrep 1mL applicator, EL(26)A/34
Becton Dickinson UK Ltd are recalling batches of ChloraPrep 2% w/v / 70% v/v cutaneous solution 1mL applicators due to a potential breach of sterility in the packaging process.
GOV.UK notice Every medicines recall is shown.
Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.